Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease

Nature Reviews Neuroscience

Volumn 20, Issue 3, 2019, Pages 148-160

  Butterfield, D Allan ^a   Halliwell, Barry ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; GLUCOSE; POLYPHENOL;

ALTERNATIVE ENERGY; ALZHEIMER DISEASE; BIOSYNTHESIS; BRAIN DAMAGE; BRAIN REGION; CITRIC ACID CYCLE; COGNITION; DOWN SYNDROME; EARLY DIAGNOSIS; ENERGY RESOURCE; ENZYME ACTIVATION; GLUCOSE METABOLISM; GLYCATION; GLYCOLYSIS; HUMAN; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; LONG TERM POTENTIATION; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; RESPIRATORY CHAIN; REVIEW; ANIMAL; BRAIN; DISEASE EXACERBATION; GLUCOSE INTOLERANCE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE PROGRESSION; GLUCOSE INTOLERANCE; GLYCOLYSIS; HUMANS; OXIDATIVE STRESS;

EID: 85061285622     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/s41583-019-0132-6     Document Type: Review

References (123)

1. Nelson, P. T., Braak, H. & Markesbery, W. R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. Exp. Neurol. 68, 1–14 (2009).
2. Martins, R. N. et al. Alzheimer’s disease: a journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies—gains from AIBL and DIAN cohort studies. J. Alzheimers Dis. 62, 965–992 (2018). This article provides a detailed review of how cohort studies have contributed to our understanding of AD.
3. Markesbery, W. R. Neuropathologic alterations in mild cognitive impairment: a review. J. Alzheimers Dis. 19, 221–228 (2010).
4. Landau, S. M. & Frosch, M. P. Tracking the earliest pathological changes in Alzheimer disease. Neurology 82, 878–883 (2014).
5. Weise, C. M. et al. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment. Neuroimage. Clin. 20, 286–296 (2018).
6. Croteau, E. et al. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer’s disease. Exp. Gerontol. 107, 18–26 (2018).
7. Arnold, S. E. et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat. Rev. Neurol. 14, 168–181 (2018). This paper is an excellent review of the links between AD, dysfunctional glucose metabolism and diabetes.
8. Halliwell, B. & Gutteridge, J. M. C. Free Radicals in Biology and Medicine 5th edn (Oxford Univ. Press, 2015). This book provides a thorough and detailed summary of the role of ROS and antioxidants in human health and disease, including neurodegenerative diseases.
9. Butterfield, D. A., Di Domenico, F. & Barone, E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim. Biophys. Acta 1842, 1693–1706 (2014).
10. Cheignin, C. et al. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 14, 450–464 (2018).
11. Halliwell, B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97, 1634–1658 (2006).
12. Butterfield, D. A. & Boyd-Kimball, D. Oxidative stress, amyloid β-peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer’s disease. J. Alzheimers Dis. 62, 1345–1367 (2018). This paper highlights the role of Aβ42 oligomers in oxidative stress in aMCI and AD brains in in vitro and in vivo models and how redox proteomics-mediated identification of oxidatively modified key brain proteins is correlated with glucose dysmetabolism, dysfunction of the proteostasis network, activation of mTORC1 and altered protein phosphorylation, all contributing to neuronal death.
13. 4 -isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer’s disease. J. Neurochem. 72, 734–740 (1999).
14. Di Domenico, F. et al. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease. Free Radic. Biol. Med. 91, 1–9 (2015).
15. Di Domenico, F., Tramutola, A. & Butterfield, D. A. Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of Alzheimer disease and other selected age-related neurodegenerative disorders. Free Radic. Biol. Med. 111, 253–261 (2017).
16. Lauderback, C. M. et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer’s disease brain: Role of Aβ1-42. J. Neurochem. 78, 413–416 (2001).
17. Martins, R. N., Harper, C. G., Stokes, G. B. & Masters, C. L. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer’s disease may reflect oxidative stress. J. Neurochem. 46, 1042–1045 (1986).
18. Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S. & Perry, G. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J. Neurosci. 15, 2653–2657 (1997).
19. Hensley, K. et al. Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146–2156 (1995).
20. Butterfield, D. A. et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer’s disease. Neurobiol. Dis. 22, 223–232 (2006).
21. Butterfield, D. A. et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci. Lett. 397, 170–173 (2006).
22. Sultana, R., Perluigi, M. & Butterfield, D. A. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic. Biol. Med. 62, 157–169 (2013). This paper describes the mechanisms of lipid peroxidation in AD and MCI brains, with resulting HNE covalently modifying and causing dysfunction in brain proteins involved in glucose metabolism and in the synaptic remodelling needed for effective neurotransmission, as revealed by redox proteomics.
23. Bradley, M. A., Markesbery, W. R. & Lovell, M. A. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic. Biol. Med. 48, 1570–1576 (2010).
24. Reed, T. T., Pierce, W. M., Turner, D. M., Markesbery, W. R. & Butterfield, D. A. Proteomic identification of nitrated brain proteins in early Alzheimer’s disease inferior parietal lobule. J. Cell. Mol. Med. 13, 2019–2029 (2009).
25. Sultana, R. et al. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment. J. Cell. Mol. Med. 11, 839–851 (2007).
26. Lyras, L., Cairns, N. J., Jenner, A., Jenner, P. & Halliwell, B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease. J. Neurochem. 68, 2061–2069 (1997).
27. Santos, R. X. et al. Nuclear and mitochondrial DNA oxidation in Alzheimer’s disease. Free Radic. Res. 46, 565–576 (2012).
28. Abolhassani, N. et al. Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer’s disease brain. Mech. Ageing Dev. 161, 95–104 (2017).
29. Shan, X. & Lin, C. L. Quantification of oxidized RNAs in Alzheimer’s disease. Neurobiol. Aging 27, 657–662 (2006).
30. Nunomura, A. et al. RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathol. 118, 151–166 (2009).
31. Li, S. et al. Soluble oligomers of amyloid β-protein facilitate hippocampal long term depression by disrupting glutamate uptake. Neuron 62, 788–801 (2009).
32. Bereczki, E. et al. Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain 141, 582–595 (2018).
33. Yang, T., Li, S., Xu, H., Walsh, D. M. & Selkoe, D. J. Large soluble oligomers of amyloid β-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J. Neurosci. 37, 152–163 (2017).
34. Di Domenico, F., Barone, E., Perluigi, M. & Butterfield, D. A. The triangle of death in Alzheimer’s disease brain: the aberrant cross-talk among energy metabolism, mammalian target of rapamycin signaling, and protein homeostasis revealed by redox proteomics. Antioxid. Redox Signal. 26, 364–387 (2017). This paper demonstrates the utility of redox proteomics to increase our understanding of molecular processes involved in neurodegeneration in the pathogenesis and progression of AD.
35. Reed, T. et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer’s disease. Neurobiol. Dis. 30, 107–120 (2008).
36. Neth, B. J. & Craft, S. Insulin resistance and Alzheimer’s disease: bioenergetic linkages. Front. Aging Neurosci. 9, 345 (2017).
37. Lee, J. et al. SIRT3 deregulation is linked to mitochondrial dysfunction in Alzheimer’s disease. Aging Cell 17, e12679 (2018).
38. Bezprozvanny, I. & Mattson, M. P. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci. 31, 454–463 (2008).
39. 2+ -calmodulin regulated effectors of microtubule stability in neuronal tissues. Biochim. Biophys. Acta 1160, 113–119 (1992).
40. Tramutola, A. et al. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment, and late-stage AD. J. Neurochem. 133, 739–749 (2015). This paper contains the first report of mTORC1 activation and consequent markers of insulin resistance and inhibition of autophagy in brains of subjects with aMCI, consistent with the notion that mTORC1 activation occurs well before dementia in the progression of AD and reflects glucose dysmetabolism early in the disease.
41. Di Domenico, F. et al. mTOR in Down syndrome: role in Aβ and Tau neuropathology and transition to redox Alzheimer disease-like dementia. Free Radic. Biol. Med. 114, 94–101 (2018).
42. Nixon, R. A. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer’s disease: inseparable partners in a multifactorial disease. FASEB J. 31, 2729–2743 (2017).
43. Rabbani, N., Xue, M. & Thornalley, P. Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics. Glycoconj. J. 33, 513–525 (2016).
44. Yan, S. D. et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 382, 685–691 (1996).
45. Pugazhenthi, S., Qin, L. & Reddy, P. H. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s Disease. Biochim. Biophys. Acta 1863, 1037–1045 (2017).
46. Piras, S. et al. Monomeric Aβ1-42 and RAGE: key players in neuronal differentiation. Neurobiol. Aging 35, 1301–1308 (2014).
47. Emendato, A. et al. Glycation affects fibril formation of Aβ peptides. J. Biol. Chem. 293, 13100–13111 (2018).
48. Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W. & Zlokovic, B. V. The role of brain vasculature in neurodegenerative disorders. Nat. Neurosci. 21, 1318–1331 (2018).
49. Bonet-Costa, V., Corrales-Diaz Pomatto, L. & Davies, K. J. A. The proteasome and oxidative stress in Alzheimer disease. Antioxid. Redox Signal 25, 886–901 (2016).
50. Keller, J. N., Hanni, K. B. & Markesbery, W. R. Impaired proteasome function in Alzheimer’s disease. J. Neurochem. 75, 438–439 (2000). An early paper that identified proteasomal dysfunction in AD.
51. Tseng, B. P., Green, K. N., Chan, J. L., Blurton-Jones, M. & LaFerla, F. M. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging 29, 1607–1618 (2008).
52. Mota, S. I. et al. Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer’s disease. Biochim. Biophys. Acta 1852, 1428–1441 (2015).
53. Hashimoto, S. & Saido, T. C. Critical review: involvement of endoplasmic reticulum stress in aetiology of Alzheimer’s disease. Open Biol. 8, 180024 (2018).
54. Di Domenico, F., Head, E., Butterfield, D. A. & Perluigi, M. Oxidative stress and proteostasis network: culprit and casualty of Alzheimer’s-like neurodegeneration. Adv. Geriatr. 2014, 1–14 (2014).
55. Choi, J. et al. Oxidative modifications and down-regulation of ubiquitin caryl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J. Biol. Chem. 279, 13256–13264 (2004).
56. Castegna, A. et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33, 562–571 (2002).
57. Gerakis, Y. & Hetz, C. Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer’s disease. FEBS J. 285, 995–1011 (2018).
58. Wiseman, F. K. et al. Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP. Brain 141, 2457–2474 (2018).
59. Lott, I. T. Neurological phenotypes for Down syndrome across the life span. Prog. Brain Res. 197, 101–121 (2012).
60. Di Domenico, F. et al. Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-A system: Insights for transition to Alzheimer disease. J. Alzheimers Dis. 44, 1107–1120 (2015).
61. Perluigi, M. et al. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome. Biochim. Biophys. Acta 1842, 1144–1153 (2014).
62. Busciglio, J. & Yankner, B. A. Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature 378, 776–779 (1995).
63. Perluigi, M. et al. Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin. Appl. 5, 167–178 (2011).
64. Barone, E., Head, E., Butterfield, D. A. & Perluigi, M. HNE-modified proteins in Down syndrome: involvement in development of Alzheimer disease neuropathology. Free Radic. Biol. Med. 111, 262–269 (2017).
65. Tramutola, A. et al. Polyubiquitinylation profile in Down syndrome brain before and after the development of Alzheimer neuropathology. Antioxid. Redox Signal. 26, 280–298 (2017).
66. Vlassenko, A. G. et al. Aerobic glycolysis and tau deposition in preclinical Alzheimer’s disease. Neurobiol. Aging 67, 95–98 (2018).
67. Caraci, F. et al. Searching for new pharmacological targets for the treatment of Alzheimer’s disease in Down syndrome. Eur. J. Pharmacol. 817, 7–19 (2017).
68. Nakamura, A. et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554, 249–254 (2018).
69. Hamlett, E. D. et al. Exosomal biomarkers in Down syndrome and Alzheimer’s disease. Free Radic. Biol. Med. 114, 110–121 (2018).
70. Winblad, B. et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 15, 455–532 (2016). This article provides a comprehensive review of the current state of AD research and prospects for treatment.
71. Golzan, S. M. et al. Retinal vascular and structural changes are associated with amyloid burden in the elderly: opthalmic biomarkers of preclinical Alzheimer’s disease. Alzheimers Res. Ther. 9, 13 (2017).
72. Koronyo, Y. et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight 2, 93621 (2017).
73. Tang, M. et al. Dominantly Inherited Alzheimer Network (DIAN) neurological manifestations of autosomal dominant familial Alzheimer disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol. 15, 1317–1325 (2016). This paper extensively describes the DIAN and how neurological studies employing the DIAN compare with results of the published literature on AD.
74. Chhatwal, J. P. et al. Dominantly inherited Alzheimer network. Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing. Brain 141, 1486–1500 (2018).
75. Casamitjana, A. et al. MRI-based screening of preclinical Alzheimer’s disease for prevention clinical trials. J. Alzheimers Dis. 64, 1099–1112 (2018).
76. Sultana, R. et al. Lymphocyte mitochondria: toward identification of peripheral biomarkers in progression of Alzheimer disease. Free Radic. Biol. Med. 65, 595–606 (2013).
77. Perluigi, M. et al. In vivo protective effects of ferulic acid ethyl ester against amyloid β-peptide (1–42)-induced oxidative stress. J. Neurosci. Res. 84, 418–426 (2006).
78. Polidori, M. C. & Nelles, G. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease-challenges and perspectives. Curr. Pharm. Des. 20, 3083–3092 (2014).
79. Butterfield, D. A., Koppal, T., Subramaniam, R. & Yatin, S. Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer’s disease. Rev. Neurosci. 10, 141–149 (1999).
80. Petersen, R. C. et al. Alzheimer’s Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352, 2379–2388 (2005).
81. Sano, M. et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer disease. N. Engl. J. Med. 336, 1216–1222 (1996).
82. Ulatowski, L. et al. Vitamin E is essential for Purkinje neuron integrity. Neuroscience 260, 120–129 (2014).
83. Spector, R. & Johanson, C. E. Vitamin transport and homeostasis in mammalian brain: focus on vitamins B and E. J. Neurochem. 103, 425–438 (2007).
84. Pei, R., Mah, E., Leonard, S. W., Traber, M. G. & Bruno, R. S. α-Tocopherol supplementation reduces 5-nitro-γ-tocopherol accumulation by decreasing γ-tocopherol in young adult smokers. Free Radic. Res. 49, 1114–1121 (2015).
85. Schaffer, S. & Halliwell, B. Do polyphenols enter the brain and does it matter? Some theoretical and practical considerations. Genes Nutr. 7, 99–109 (2012).
86. Mattson, M. P., Son, T. G. & Camandola, S. Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Response 5, 174–186 (2007).
87. Begum, A. N. et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s disease. J. Pharmacol. Exp. Ther. 326, 196–208 (2008).
88. Nelson, K. M. et al. The essential medicinal chemistry of curcumin. J. Med. Chem. 60, 1620–1637 (2017).
89. Ma, Q. & He, X. Molecular basis of electrophilic and oxidative defence: promises and perils of Nrf2. Pharmacol. Rev. 62, 1055–1081 (2012).
90. Branca, C. et al. Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer’s disease. Hum. Mol. Genet. 26, 4823–4835 (2017).
91. Long, L. H., Hoi, A. & Halliwell, B. Instability of, and generation of hydrogen peroxide by, phenolic compounds in cell culture media. Arch. Biochem. Biophys. 501, 162–169 (2010).
92. Halliwell, B., Cheah, I. K. & Tang, R. M. Y. Ergothioneine, a diet-derived antioxidant with therapeutic potential. FEBS Lett. 592, 3357–3366 (2018).
93. Cheah, I. K., Tang, R. M., Yew, T. S., Lim, K. H. & Halliwell, B. Administration of pure ergothioneine to healthy human subjects: uptake, metabolism, and effects on biomarkers of oxidative damage and inflammation. Antioxid. Redox Signal. 26, 193–206 (2017).
94. Valero, T. Mitochondrial biogenesis: pharmacological approaches. Curr. Pharm. Design 20, 5507–5509 (2014).
95. Huang, Z. et al. Novel derivative of bardoxolone methyl improves safety for the treatment of diabetic nephropathy. J. Med. Chem. 60, 8847–8857 (2017).
96. Ng, L. F. et al. The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease. Free Radic. Biol. Med. 71, 390–401 (2014).
97. Raefsky, S. et al. Deuterated polysaturated fatty acids reduce brain lipid peroxidation and hippocampal amyloid beta-peptide levels, without discernable behavioral effects in an APP/PS1 mutant transgenic mouse model of Alzheimer disease. Neurobiol. Aging 66, 165–176 (2018).
98. Claxton, A. et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer’s disease. J. Alzheimers Dis. 35, 789–797 (2013).
99. Barone, E. et al. Biliverdin reductase-A mediates the beneficial effects of intranasal insulin in Alzheimer disease. Mol. Neurobiol. 10.1007/s12035-018-1231-5 (2018). This paper improves our mechanistic understanding of the beneficial effects of intranasal insulin in the cognitive improvement of patients with AD and MCI by demonstrating in the 3xTg mouse model of AD that BVRA was prevented from early impairment in adult mice, or rescued from damage in aged mice, following intranasal insulin that was correlated with improved insulin signalling, decreased nitrosative stress and improved cognition.
100. Barone, E., Di Domenico, F., Mancuso, C. & Butterfield, D. A. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it’s time for reconciliation. Neurobiol. Dis. 62, 144–159 (2014).
101. Barone, E. et al. Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: a new paradigm. Free Radic. Biol. Med. 91, 127–142 (2016).
102. Cunnane, S. C. et al. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease. Ann. NY Acad. Sci. 1367, 12–20 (2016).
103. Wu, L., Zhang, X. & Zhao, L. Human ApoE isoforms differentially modulate brain glucose and ketone body metabolism: implications for Alzheimer’s disease risk reduction and early intervention. J. Neurosci. 38, 6665–6681 (2018).
104. Lu, D. C. et al. A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor. Nat. Med. 6, 397–404 (2000).
105. Nikolaev, A., McLaughlin, T., O’Leary, D. D. & Tessier-Lavigne, M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981–989 (2009).
106. Intlekofer, K. A. & Cotman, C. W. Exercise counteracts declining hippocampal function in aging and Alzheimer’s disease. Neurobiol. Dis. 57, 47–55 (2013).
107. Opii, W. O. et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and program of behavioral enrichment: relevance to Alzheimer’s disease. Neurobiol. Aging 29, 51–70 (2008).
108. Solomon, A. et al. Effect of the Apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol. 75, 462–470 (2018).
109. Scarmeas, N., Anastasiou, C. A. & Yannakoulia, M. Nutrition and prevention of cognitive impairment. Lancet Neurol. 17, 1006–1015 (2018).
110. Fyfe, I. APOE ε4 affects cognitive decline but does not block benefits of healthy lifestyle. Nat. Rev. Neurol. 14, 25 (2018).
111. van Dalen, J. W. et al. Effect of long-term vascular care on progression of cerebrovascular lesions: magnetic resonance imaging substudy of the PreDIVA trial (prevention of dementia by intensive vascular care). Stroke 48, 1842–1848 (2017).
112. Chu, C. S. et al. Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci. Rep. 8, 5804 (2018).
113. Butterfield, D. A., Barone, E. & Mancuso, C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol. Res. 64, 180–186 (2011).
114. Barone, E. et al. Biliverdin reductase-A: a novel drug target for atorvastatin in a dog preclinical model of Alzheimer disease. J. Neurochem. 120, 135–146 (2012).
115. Butterfield, D. A. & Boyd-Kimball, D. Redox proteomics and amyloid β-peptide: Insights into Alzheimer disease. J. Neurochem. 10.1111/jnc.14589 (2018).
116. Gordon, B. A. et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol. 17, 241–250 (2018). This paper reports longitudinal PET and MRI results on brains in persons with autosomal dominantly inherited AD obtained regularly 22 years before up to 3 years after the onset of AD symptoms and demonstrates the temporal order of brain pathology observed prior to symptoms.
117. Zhang, H. et al. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease. Alzheimers Res. Ther. 10, 80 (2018).
118. Davies, M. J. Protein oxidation and peroxidation. Biochem. J. 473, 805–825 (2016). This article provides a very good account of the mechanisms and consequences of oxidative protein damage.
119. Milne, G. L., Dai, Q. & Roberts, L. J. 2nd. The isoprostanes—25 years later. Biochim. Biophys. Acta 1851, 433–445 (2015). This paper provides an excellent review of the formation of isoprostanes in biological systems and their role as biomarkers of lipid peroxidation in disease.
120. Dizdaroglu, M., Coskun, E. & Jaruga, P. Measurement of oxidatively induced DNA damage and its repair, by mass spectrometric techniques. Free Radic. Res. 49, 525–548 (2015). This article provides a detailed and comprehensive review of mechanisms of oxidative DNA damage and how it can be measured in vivo.
121. Ishii, T. et al. Specific binding of PCBP1 to heavily oxidized RNA to induce cell death. Proc. Natl Acad. Sci. USA 115, 6715–6720 (2018).
122. Wang, J.-X. et al. Oxidative modification of miR-184 enables it to target Bcl-xL and Bcl-w. Mol. Cell 59, 50–61 (2015).
123. Dai, D.-P. et al. Transcriptional mutagenesis mediated by 8-oxoG induces translational errors in mammalian cells. Proc. Natl Acad. Sci. USA 115, 4218–4222 (2018).